Fennec Pharmaceuticals Inc (FENC)

$4.61

+0.07

(+1.54%)▲

Live

Performance

  • $4.61
    $4.68
    $4.61
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.5%

    Upside

    1.5%

    downward going graph
  • $4.09
    $11.92
    $4.61
    downward going graph

    11.28%

    Downside

    52 Weeks Volatility :65.69%

    Upside

    61.33%

    downward going graph

Returns

PeriodFennec Pharmaceuticals IncIndex (Russel 2000)
3 Months
-30.9%
0.0%
6 Months
-51.6%
0.0%
1 Year
-33.24%
0.0%
3 Years
-48.35%
-23.0%

Highlights

Market Capitalization
127.3M
Book Value
-$0.05
Earnings Per Share (EPS)
0.07
PE Ratio
66.43
Wall Street Target Price
15.5
Profit Margin
5.59%
Operating Margin TTM
-69.39%
Return On Assets TTM
8.88%
Return On Equity TTM
-1005.59%
Revenue TTM
48.9M
Revenue Per Share TTM
1.81
Quarterly Revenue Growth YOY
118.39999999999999%
Gross Profit TTM
1.4M
EBITDA
-13.0M
Diluted Eps TTM
0.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.12
EPS Estimate Next Year
0.17
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
0.01

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Fennec Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 236.23%

Current $4.61
Target $15.50

Technicals Summary

Sell

Neutral

Buy

Fennec Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc
-11.15%
-51.6%
-33.24%
-48.35%
-0.44%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc
66.43
66.43
NA
0.12
-10.06
0.09
NA
-0.05
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc
Buy
$127.3M
-0.44%
66.43
5.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Fennec Pharmaceuticals Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 116.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 93.2%

Institutional Holdings

  • Southpoint Capital Advisors LP

    14.90%

  • Sonic GP LLC

    8.80%

  • DG Capital Management, LLC

    5.97%

  • Solas Capital Management LLC

    4.90%

  • BlackRock Inc

    4.34%

  • Vanguard Group Inc

    3.75%

Company Information

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

Organization
Fennec Pharmaceuticals Inc
Employees
29
CEO
Mr. Rostislav Raykov
Industry
Health Technology

Discover More

FAQs